Kalium

Study feasability, measured by adequacy and efficiency of recruitment strategies

Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score from Baseline to Week 20

Progression of kidney cysts by change in total kidney volume (TKV) from baseline to 12 months

Population-based pharmacokinetic model for fisetin and metabolites

Detection of H pylori eradication difference among the three groups through stool antigen test 4 weeks after completion of therapy.

Change in Body Weight (kg)

Change in potassium levels (mmol/L)

Basic data

Proportions of subjects achieving WI-NRS

Pharmacokinetic profile of key coffee biologically active compounds and their metabolites after consuming a coffee drink, a coffee tablet and control.

Urine specific gravity

Change in Total Volumetric Bone Mineral Density (BMD) - Distal Radius

Participant Adherence

To evaluate the rate of Undetectable Measurable Residual Disease (uMRD) at 6 and 12 months as per International Myeloma Working Group (IMWG) criteria evaluated by the investigators of elranatamab in patients with relapsed/refractory multiple myeloma.

Change in Urine Albumin-to-Creatinine Ratio (UACR)

Biomarker-estimated (-)-epicatechin and flavanol intake

Dietary adherence to PLAFOND vs. standard-of-care renal diet assessed by diet diaries

Effect of a single oral high-sodium chloride load or a partial substitution by potassium chloride on retinal vessel diameter and the flicker-light-induced retinal vessel dilatation.

Change in Nutrition Knowledge

Change From Baseline in Weekly Average Pain Intensity Assessed by the Numeric Pain Rating Scale (NPRS) at Week 12

Effect on renal function

Incidence of adverse events (AEs）

Safety endpoint will be assessed through collection and analysis of adverse events.

24 hours urinary total protein

Change in FFM (%) in proportion to TBWL

Respiratory symptoms: EXACT

change in systolic 24-h ambulatory BP [whole study group]

Triacylglcerides, mmol/l (group A, B)

Insulin resistance

Estimated sodium concentration in skin and muscle

Change From Baseline to Week 26 in Right Ventricular Stroke Volume (RVSV) Assessed by Pulmonary Artery Flow Magnetic Resonance Imaging (MRI)

Rate of extubation (for intubated patients)

Maximum Observed Plasma Concentration (Cmax) After Administration of AMB Under Fasted Condition

Change in 24 hour urine citrate

Change from baseline in parent-reported anxious symptoms at 3 weeks follow-up

Change in the biochemical parameters related to kidney injury, dehydration, inflammation, and cardiac damage

Renal Clearance (CLr) of Metformin

Maximum power

Relative Change From Baseline in Whole Liver Fat at Day 15 as Assessed by Magnetic Resonance Imaging (MRI) - Proton Density Fat Fraction (PDFF)

Change From Baseline in UPCR at Week 12

Percent Change From Baseline in Blood Eosinophils Over Time

Part A- Session 1: Peak Standardized Uptake Values (SUV) in Focal Anatomical Regions of the Heart Following 80-200 mg Dose of Anti-SAP mAb

Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs (STEAEs)

Part A: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

The primary outcome is the change in The Western Ontario and McMaster Universities Arthritis Index (WOMAC), Pain subscale (Numeric Rating Scale)

To define the germline and/or somatic genetic events causing Primary Aldosteronism (PA) in Blacks.

Part 1A, Part 1B: Maximum tolerated dose (MTD) of SM08502 based on the frequency and severity of dose-limiting toxicities (DLTs)

Percentage of Participants With Loss of Asthma Control Over Weeks 0-16

Number of Patients Who Experienced Adverse Events (AEs) in the MP

Total number of patients recruited over a 6 month period

Change From Baseline J-Tpeakc With "Balanced Ion Channel" Drugs (Ranolazine, Verapamil, Lopinavir / Ritonavir)

Maximum Observed Plasma Concentration (Cmax) of Mepolizumab

Number of Participants With Non-serious Adverse Events (nSAEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability

Mean Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24

Change in BMI SDS (Week 0, Week 56)

Blood Oxygen Level Dependent (BOLD) Signal by Functional Magnetic Resonance Imaging (fMRI) Visual Nauseogenic Task

Time From Randomisation to Inadequate Glycaemic Control and Need for Treatment Intensification

Composite time spent in ideal potassium range

Number of Participants With Contrast Induced-Acute Kidney Injury

DB Period: Change From Baseline in Disease Activity Score for 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 24

Part A: Number of Participants With at Least One Non-serious Adverse Event (AE), Serious Adverse Event (SAE), or Drug-related Adverse Event

Number of Participants With Serious Adverse Events (SAEs) and Common (>=5%) Non-serious Adverse Events- Part 1

Number of Participants With Adverse Events (AEs) Related to Cytokine Release Syndrome (CRS)

Incidence of hypokalemia ≤3.5mEq/L

Change in abdominal adipose tissue (visceral) as measured by computed tomography (cm2)

Change From Baseline in Proteinuria Levels at Week 28

Number of participants experiencing adverse events (AEs)

Self-reported energy intake from automated self-administered 24-hour dietary recall (ASA24), Diet History Questionnaire (DHQ)-II, and 4-day food record

Change in Endothelium-dependent flow-mediated dilation comparing (1) high sodium, low potassium intake and (2) low sodium, high potassium intake with low sodium, low potassium intake.

Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12

Progression-Free Survival (PFS) as Assessed by the Investigator (INV)

Change in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8

Twenty-four hour urinary Na/K ratio (AUC(0-24)).

Change From Baseline in Endoscopic Score (as Measured by Modified Baron Score) at Week 8

Change From Baseline in Urinary Albumin Creatinine Ratio (UACR) at Week 12

Urinary excretion (over 24 hours) of C-terminal cross-linking telopeptides of type I collagen (CTX)

6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 16

Percentage of Participants Responding (Plasma HIV-1 Ribonucleic Acid [RNA] Levels Less Than 40 Copies/Milliliter [mL]) at Week 48 Based on the Food and Drug Administration (FDA) Time to Loss of Virologic Response (TLOVR) Algorithm

HIV-1 RNA Level

Number of participants with adverse events (AEs) and serious adverse events (SAEs)

Change from Randomization at Week 6 in Bech subscale (6-item of 17-item Hamilton depression rating [HAMD-17] scale) score

Number of participants with adverse events

Maximum Observed Plasma Concentration (Cmax) and Plasma Concentration 24 Hours Post-dose (Cmin) of EFV at Week 2 - Pharmacokinetic Evaluable Population

Mean Change From Baseline in Calculated Glomerular Filtration Rate (GFR) With Imputed Values to 12 Months Post Randomization - All Randomized Participants (Intent-to-Treat Population)

Progression of Acute Coronary Syndrome to Myocardial Infarction

Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 48, as a Function of APOE ε4 Status in APOE4 Negatives Cohort

Mean Change From Baseline in Liver Biopsy Immunohistochemical Marker of Hepatic Stellate Cell (HSC) Activation and Collagen Synthesis at Week 52

Maximum Plasma Concentration (Cmax)

Short-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations

Change From Baseline in Viral Load (log10 Reduction) at Week 12

Changes in echocardiographic left ventricular diastolic volume